Name /bks_53161_deglins_md_disk/humanpapillomavirusvacci 03/07/2014 08:28AM Plate # 0-Composite pg 1 # 1

1 Contraindications/Precautions
Contraindicated in: Hypersensitivity; Thrombocytopenia/bleeding disorder; OB: PDF Page #1
HUMAN PAPILLOMAVIRUS VACCINE Limited data available; use only if potential benefit justifies potential risk to fetus.
Use Cautiously in: Current/recent febrile illness; Immunosuppression maypan-
(hyoo-man pa-pil-lo-ma)
tibody response; Lactation: Excretion into breast milk unknown; Pedi: Children
human papillomavirus quadrivalent (types 6, 11, ⬍9 yr (safety not established).

16, and 18) vaccine, recombinant Adverse Reactions/Side Effects

Gardasil Neuro: fainting. Local: injection site reactions. Misc: ANAPHYLAXIS (RARE).
human papillomavirus bivalent (types 16 and 18) Interactions
Drug-Drug: Immunosuppressants or antineoplastics may p antibody re-
vaccine, recombinant sponse.
Cervarix
Classification Route/Dosage
Therapeutic: vaccines/immunizing agents IM (Adults and Children — males and females 9– 26 yr): Gardasil— Three
0.5 mL doses at 0, 2, and 6 mo.
IM (Adults and Children — females 9– 25 yr): Cervarix— Three 0.5 mL doses
at 0, 2, and 6 mo.
Indications
Gardasil: Prevention of cervical, vulvar, vaginal, and anal cancers and genital warts NURSING IMPLICATIONS
(in females) and anal cancer and genital warts (in males). Cervarix: Prevention of
cervical cancer. Assessment
● Assess vital signs prior to administration. Do not administer to patient with a cur-
Action rent or recent febrile illness; low grade fever (⬍100⬚F) and mild upper respira-
Vaccination results in antibodies to HPV viruses that are causative agents for cervical, tory infection are usually not contraindicated.
vulvar, vaginal, and anal cancers and genital warts. Therapeutic Effects: Preven- ● Monitor patient for 15 min following injection for fainting. Patient should remain
tion of cervical, vulvar, vaginal, and anal cancers and genital warts. lying down or seated to prevent falls or injury.
Pharmacokinetics Potential Nursing Diagnoses
Absorption: Well absorbed following IM administration. Risk for infection (Indications)
Distribution: Unknown.
Metabolism and Excretion: Unknown. Implementation
Half-life: Unknown. ● Vaccine is not intended for treatment of active genital warts or cervical cancer and
TIME/ACTION PROFILE (antibody response) will not protect from diseases not caused by HPV.
● IM: Gardasil: Prefilled syringe is for single use; do not use for more than one per-
ROUTE ONSET PEAK DURATION
son. Administer as supplied; do not dilute; administer full dose. Shake well prior
IM unknown 6 mo* unknown to administration to maintain suspension of vaccine. Solution is cloudy and white;
*After third vaccination. do not administer solution that is discolored or contains particulate matter. If us-
⫽ Canadian drug name. ⫽ Genetic Implication. CAPITALS indicate life-threatening, underlines indicate most frequent. Strikethrough ⫽ Discontinued.
Name /bks_53161_deglins_md_disk/humanpapillomavirusvacci 03/07/2014 08:28AM Plate # 0-Composite pg 2 # 2

2
ing single-dose vial, withdraw 0.5 mL dose and administer entire contents of sy- PDF Page #2
ringe. Administer intramuscularly in the deltoid or in the high anterolateral area of
the thigh.
● IM: Cervarix: Prefilled syringe is for single use; do not use for more than one per-
son. Administer as supplied; do not dilute; administer full dose. Shake vial or sy-
ringe well before use. Solution is a turbid, white suspension; do not administer if it
is discolored or contains particulate matter. The tip cap and rubber plunger of
needleless prefilled syringes contain dry natural latex rubber; may cause allergic
reactions in latex sensitive individuals. Vial stopper does not contain latex.
Patient/Family Teaching
● Provide information about vaccine and the importance of completing immuniza-
tion series unless contraindicated to patient and guardian.
● Inform patient that vaccine does not replace routine cervical cancer screening or
prevent other sexually transmitted diseases; such screening should be continued
as usual.
● Advise patient to notify health care professional of all Rx or OTC medications, vita-
mins, or herbal products being taken and to consult with health care professional
before taking other medications.
● Advise patient to notify health care professional if pregnancy is planned or sus-
pected. Women exposed to Gardasil vaccine during pregnancy are encouraged to
call manufacturer pregnancy registry at 800-986-8999. Women exposed to Cer-
varix vaccine during pregnancy are encouraged to call manufacturer pregnancy
registry at 800-452-9622.
● Instruct patient to report any adverse reactions to health care professional.

Evaluation/Desired Outcomes
● Prevention of cervical cancer, genital warts, cervical adenocarcinoma in situ, cer-
vical, vulvar, anal, and vaginal intraepithelial neoplasia caused by HPV.
Why was this drug prescribed for your patient?

䉷 2015 F.A. Davis Company